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Acidicmammalian chitinase (AMCase) is produced in
the lungduringallergic inflammation andasthma, and
inhibition of enzymatic activity has been considered
as a therapeutic strategy. However, most chitinase
inhibitors are nonselective, additionally inhibiting
chitotriosidase activity. Here, we describe bisdionin
F, a competitive AMCase inhibitor with 20-fold selec-
tivity for AMCase over chitotriosidase, designed
by utilizing the AMCase crystal structure and dicaf-
feine scaffold. In amurinemodel of allergic inflamma-
tion, bisdionin F-treatment attenuated chitinase
activity and alleviated the primary features of allergic
inflammation including eosinophilia. However, selec-
tive AMCase inhibition by bisdionin F also caused
dramatic and unexpected neutrophilia in the lungs.
This class of inhibitorwill be a powerful tool to dissect
the functions ofmammalian chitinases in disease and
represents a synthetically accessible scaffold to
optimize inhibitory properties in terms of airway
inflammation.
INTRODUCTION
Chitin, the second most abundant polysaccharide in nature, is
a principal component of the arthropod exoskeleton, nematode
eggshell, and fungal cell wall. Although mammals themselves do
not synthesize chitin, they are continually exposed to this
polymer through inhalation and exposure to chitin-containing
pathogens. Chitin accumulation is limited through hydrolysis of
b(1/4) glycosidic bonds by chitinases, members of the evolu-
tionary conserved glycoside hydrolase family 18 (GH18).
Mammals have two genes encoding active chitinases, chitotrio-
sidase (CHIT1) and acidic mammalian chitinase (AMCase), that
represent an ancient gene duplication event and show sequence
homology to bacterial chitinases (Bussink et al., 2007). More
recent gene duplications have yielded the homologous chiti-Chemistry & Biology 18,nase-like proteins (CLPs) with mutations within the enzymatic
machinery rendering the catalytic site inactive (Zaheer-ul-Haq
et al., 2007). Although the functions of both chitinases and
CLPs in mammals are still poorly understood, it is becoming
clear that their expression is regulated in both innate and adap-
tive immune responses. CHIT1, which is expressed exclusively
in phagocytes (Boot et al., 2005), is thought to play an important
role in the mammalian innate immune response against fungi,
bacteria, and other pathogens (Barone et al., 2003; Labadaridis
et al., 2005). Conversely, increased production of AMCase and
CLPs Ym1, Ym2, and BRP-39 in rodents and YKL-39 and
YKL-40 in humans is a prominent feature of Th2-driven patholo-
gies, including infection, allergic inflammation, and asthma
(reviewed in Sutherland et al., 2009).
AMCase was first described to be expressed in the gastroin-
testinal tract and lungs of rodents and humans (Boot et al.,
2001). AMCase is expressed in tissue macrophages and epithe-
lial cells, with its production driven by Th2-cytokines IL-4 and
IL-13 (Zhu et al., 2004). Early exploration of mammalian chitinase
function implicated AMCase as a mediator of Th2-driven allergic
airway diseases following the use of the chitinase inhibitor allosa-
midin, a pseudotrisaccharide natural product derived from
Streptomyces species (Sakuda et al., 1986), in murine models
(Zhu et al., 2004). Treatment of allergen-challenged mice with
allosamidin or demethylallosamidin significantly reduced eosino-
philia, a hallmark of allergic inflammation (Matsumoto et al., 2009;
Zhu et al., 2004). Although both compounds inhibit chitinase
activity in vivo, only demethylallosamidin treatment reduces
allergen or IL-13-induced airway hyperresponsiveness. Despite
beneficial actions in models of Th2-driven allergic inflammation,
the therapeutic potential of these compounds is limited due to
their expensive and complex synthesis and commercial unavail-
ability. In addition, allosamidin has a broad range of activity
against all family 18 chitinases (Berecibar et al., 1999) and
possesses physicochemical properties that are not compatible
with a drug-like compound, such as high molecular weight
(604.7 Da), an undesirably low clogP (4.7), and poor ligand effi-
ciency (0.25 kcal$mol1$atom1 for fungal chitinase) (Vaaje-
Kolstad et al., 2004). Allosamidin is a more effective inhibitor of
CHIT1 than AMCase (IC50 murine CHIT1 [mCHIT1] 50 nM and569–579, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 569
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Chemical Dissection of AMCase Functionmurine AMCase [mAMCase] 400 nM) (Zheng et al., 2005; Boot
et al., 2001). This is of particular concern as CHIT1 is not an
effector molecule in allergic inflammation and is rather regarded
as a host-defense mechanism against chitin-containing patho-
gens (reviewed in Sutherland et al., 2009). Thus, there is a need
to identify compounds that are drug-like selective inhibitors of
AMCase that can be used in animal models to dissect the roles
of the chitinases in allergic airway inflammation and potentially
further develop as anti-asthma therapies.
We recently identified xanthine derivatives as promising leads
for GH18 inhibitors (Rao et al., 2005) and subsequently devel-
oped a low micromolar chitinase inhibitor composed of two
linked caffeine molecules (bisdionin) with desirable drug-like
properties, a crystallographically defined binding mode, and
excellent synthetic accessibility (Schuttelkopf et al., 2006).
Here, we describe the rational design of a novel AMCase inhib-
itor, bisdionin F, with 20-fold selectivity for AMCase over
CHIT1 and demonstrate in vivo activity in a mouse model of
acute allergic inflammation. Bisdionin F treatment in allergen-
challenged mice reduced eosinophil recruitment and measure-
ments of ventilatory function. Unexpectedly however, treatment
with bisdionin F also resulted in neutrophilia and changes to
expression of genes associated with remodeling. These studies
highlight the complex mechanistic pathways surrounding the
therapeutic inhibition of AMCase activity. Nonetheless, the
potent selective activity of bisdionin F in vitro and in vivo and
its relatively easy synthesis makes this inhibitor an invaluable
tool for the chemical biological dissection of the roles of the
different mammalian chitinases.
RESULTS
Rational Design of Bisdionin F, a hAMCase
Selective Inhibitor
A recent report described the reduction of airway eosinophilia
upon inhibition of total bronchoalveolar chitinase activity with
the natural product chitinase inhibitor allosamidin (Zhu et al.,
2004). We recently described the bisdionins, dixanthine deriva-
tives that aremicromolar inhibitors of family 18 chitinases (Schut-
telkopf et al., 2006).Ahigh-resolutioncrystal structureofbisdionin
B (C2-dicaffeine) complexedwithAspergillus fumigatus chitinase
B1 (AfChiB1)wassolvedand revealed thebindingmodeofbisdio-
nin B (Schuttelkopf et al., 2006). While being less energetically
favorable, the caffeine linker length of these molecules could be
modified to alleviate strain and result in a more potent inhibitor
(Schuttelkopf et al., 2011). The most potent of these, bisdionin
C (Figure 1A), is a drug-like molecule as assessed by Lipinski’s
rule of five: it has six hydrogen bond acceptors and no hydrogen
bond donors, a molecular weight of 400.4 Da, a clogP of approx-
imately 0, and a ligand efficiency of 0.41 kcal$mol1$atom1
against AfChiB1 (Schuttelkopf et al., 2011). We investigated
whether bisdionin C would inhibit human AMCase (hAMCase)
and/or human chitotriosidase (hCHIT1). Assessment of chitinase
activity usinga fluorescent substrate revealed thatwhile bisdionin
C inhibits hAMCase and hCHIT1 in the micromolar range, it does
so with no apparent selectivity (Figure 2A).
To facilitate structure-guided optimization of thebisdionin scaf-
fold into a potent, selective hAMCase inhibitor, the crystal struc-
ture of the hAMCase-bisdionin C complex was determined to570 Chemistry & Biology 18, 569–579, May 27, 2011 ª2011 Elsevier2.2 A˚ resolution (Table 1 and Figure 1C). The native structure of
hAMCase has recently been reported (Olland et al., 2009), giving
an rmsd of 0.80 A˚ with the structure reported here. The loops on
the AMCase TIM barrel [(ba)8 fold] produce a deep active site cleft
similar to other ‘‘bacterial-type’’ family 18 chitinases. Bisdionin C
spans the1,2,and3GlcNAcbindingsubsitesof theAMCase
chitooligosaccharide substrate (Figure 1C). The methyl xanthine
units bind at the bottom of the active site, stacking on the indole
groups of Trp31 and Trp360 (Figure 1C). The hydroxyl group of
Tyr212 forms a hydrogen bond with N9, whereas the backbone
N of Trp99 forms a hydrogen bond with O6. Water-mediated
hydrogen bonds are formed between the carboxyl group of
Asp213 and O2 and between the backbone oxygen and nitrogen
atoms of Gly97 and Phe101, respectively, and bisdionin C O60.
Although hCHIT1 and hAMCase catalytic domains share 57%
sequence identity, there are two amino acids near the catalytic
machinery that are different in hAMCase, His269 (Arg269 in
hCHIT1) and Ile300 (Met300 in hCHIT1) (Figure 1C). Interestingly,
the N7 methyl group of bisdionin C appears to impose an unfa-
vorable conformation of Asp138, a key catalytic residue that
hydrogen bonds the catalytic acid (Glu140)/substrate N-acetyl
group and stabilizes the oxazolinium ion reaction intermediate
during catalysis (Brameld et al., 1998; Terwisscha van Scheltinga
et al., 1995; van Aalten et al., 2001) (Figure 1). Given the unfavor-
able interactions of the N7 methyl group and the nonconserved
amino acid substitutions on the opposite side of the xanthine
moiety, we explored the effects of the N7 methyl group on
potency and selectivity. We synthesized bisdionin F, the N7-de-
methylated derivative of bisdionin C (Figure 1A). A 2.25 A˚ crystal
structure of the hAMCase-bisdionin F complex reveal that
Asp138 now adopts the ‘‘up’’ conformation, generating an
additional hydrogen bond with the N7 of the xanthine in the 1
subsite, and also interacting with the catalytic acid (Glu140).
The inhibitor bisdionin Fwas shown to further increase hAMCase
inhibition by over one order of magnitude compared to bisdionin
C, competitively inhibiting the enzyme with a Ki = 420 ± 10 nM
(Figure 1B). The inhibitor shows this improved inhibition only
toward hAMCase, not hCHIT1 (IC50 = 17 mM), thus introducing
20-fold selectivity (Figure 2A). It should be noted that hAMCase
possesses a more negatively charged active site, generated by
the Arg269 (hCHIT1) to His269 (hAMCase) substitution, also
lowering the pH optimum of the enzyme. Thus, electrostatic
effects may explain why the imidazole moiety, generated by
removing the methyl group, is better accommodated by the
hAMCase enzyme.
Bisdionin F Reduces Chitinase Activity in a Murine
Model of Allergic Inflammation
To verify that, as expected, bisdionin F would have similar
activity against the mouse enzyme, recombinant mAMCase
was stably expressed in COS-7 cells. After 10 min incubation,
bisdionin F treatment resulted in a concentration-dependent
inhibition of mAMCase activity with an IC50 of 2.2 ± 0.2 mM
(Figure 2B). To test the in vivo efficacy of bisdionin F, a well-
established model of airway lung inflammation was used, in
which mice are first sensitized with ovalbumin (OVA) i.p. and
then challenged in the airways, leading to increased chitinase
activity in the lung tissue (Zhu et al., 2004). Enzymatic activity
in lung homogenates of mice treated with 5 mg/kg bisdionin FLtd All rights reserved
Figure 1. Activity of Bisdionin F and a Struc-
tural Comparison of Bisdionin-hAMCase
Complexes
(A) Chemical structures and atom numbering
of bisdionin C and bisdionin F are shown with
the differing methyl/hydrogen moieties highlighted
in red.
(B) Lineweaver-Burk plot showing bisdionin F
inhibition of hAMCase at different concentrations.
The data are compatible with a competitive inhi-
bition model, giving a Ki of 420 ± 10 nM.
(C) Stereo figures of the active sites (monomer A)
of the hAMCase-bisdionin C (top) and hAMCase-
bisdionin F (bottom) complexes. Unbiased Fo-Fc
4c electron density maps are contoured at 2.5s.
Protein side chains, glycerol, and ligand mole-
cules are shown as a stick models with gray,
yellow, and magenta C atoms, respectively.
hAMCase residues not conserved compared to
CHIT1 are shown with orange C atoms. Water
molecules interacting with the ligand are shown as
orange spheres and hydrogen-bonding interac-
tions are shown as dotted green lines. The
second, less-defined, ligand molecules stacking
against Trp99 and Trp218 are omitted for clarity.
N-acetyl glucosamine residues taken from the
HCGP-39 in complex with chitin (PDB ID 1HJW)
and Asp138 in the ‘‘up-conformation’’ are shown
as stick models with transparent green C atoms.
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Chemical Dissection of AMCase Function(Figure 3A) was assessed in this model. As previously reported,
chitinase activity significantly increases upon allergic challenge,
as assayed approximately 24 hr after the last challenge, while
treatment with bisdionin F significantly reduced chitinase activity
in the lungs of both control PBS and OVA-challenged mice.
Bisdionin F Modulates Allergen-Induced Inflammation
To assess the impact of AMCase inhibition on allergen-induced
inflammation, cellular infiltrate into the bronchoalveolar lavageChemistry & Biology 18, 569–579, May 27, 2011fluid (BALF) was examined on cytospins
from vehicle and bisdionin F-treated
animals (Figures 3B and 3C). As expected,
acuteOVA challenge induced a significant
increase in eosinophils, lymphocytes,
and macrophages in the lavage fluid
compared to PBS-challengedmice. Strik-
ingly, bisdionin F-treated allergic mice
were found to have significantly reduced
total cell airway infiltrates (Figure 3B,
p < 0.01 compared to vehicle treatment),
whereas cell numbers in PBS-challenged
animals were not altered with chitinase
inhibition. Differential counts of cells
recovered from the BALF revealed a
reduction in the number of lymphocytes
and eosinophils following chitinase inhibi-
tion (Figure 3C). However, the most unan-
ticipated result of bisdionin F treatment
was a 4-fold increase in neutrophil cell
number compared to vehicle-treated
OVA-challenged mice (Figure 3C).Changes to inflammatory infiltrates were examined in hema-
toxylin- and eosin-stained lung sections (Figures 3D and 3E).
PBS-challenged mice had similar lung structure and cellular
composition, whether treated with bisdionin F or vehicle (Figures
3Di and 3Dii). Allergen challenge resulted in inflammatory cell
influx into the lamina propria, perivascular, and peribronchiolar
regions of the lung. Following treatment with bisdionin F in
allergic animals, inflammatory influx into the lung tissue was
more striking (Figures 3D and 3E). Staining with naphthol AS-Dª2011 Elsevier Ltd All rights reserved 571
Inhibitor hAMCase hCHIT1
Bisdionin C
Bisdionin F
20 ± 1 μM
0.92 ± 0.04 μM
(0.42 ± 0.01 μM)
8.3 ± 0.7 μM
17.1 ± 1 μM
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0
500
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1500
2000
       AMCase
AMCase Activity
(4MU/hr/mL)
log [Inhibitor]
A
B Figure 2. Chitinase Inhibition by Bisdionin
Compounds
(A) IC50 values (Ki values are shown in parenthesis) of
bisdionin C and F compounds against hAMCase and
hCHIT1. All values are given in micromolar.
(B) Bisdionin F inhibits recombinant mAMCase enzymatic
activity in vitro. Chitinase activity was determined using
a fluorescent 4-methylumbelliferyl (4-MU) substrate. An
AMCase expressing COS-7 cell-free supernatant was
used as a source of enzymatically active recombinant
mAMCase. rAMCase, in the presence of 4-MU substrate,
was incubated with DMSO vehicle or increasing concen-
trations of bisdionin F for 10 min at 37C. Chitinase activity
is measured relative to the amount of substrate hydro-
lysed/hr/mL sample. IC50 = 2.21 ± 0.18 mM.
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Chemical Dissection of AMCase Functioncholoracetate esterase, a stain specific for neutrophil granulo-
cytes, revealed predominant neutrophil influx in bisdionin F
OVA-challenged mice (Figure 3F), consistent with the analysis
of the BALF (Figure 3C).
To investigate the cause of the bisdionin F-induced neutro-
philic response, cytokine and chemokine secretion from
OVA-specific tLN cell cultures were examined with Luminex
multiplex bead array. Potent neutrophil chemotactic factors KC
(murine IL-8 equivalent) and IL-17 were not significantly altered
in tLN cultures from chitinase inhibitor treated allergic mice
(data not shown). However, both the secretion and expression
of chemokine macrophage inhibitory protein-1 alpha (MIP-1a),
also a neutrophil chemoattractant, were enhanced by bisdionin
F treatment in OVA-challenged animals (Figures 3G and 3H).
MIP-1a levels were not altered by OVA-challenge alone, corre-
lating with a lack of significant neutrophil recruitment in these
mice (Figure 3C).Altered Eosinophil Recruitment Following Bisdionin F
Treatment Is Dose Dependent
At a dose of 5 mg/kg, bisdionin F decreased eosinophil cell
number and increased neutrophil cell number, resulting in an
unfavorable cell recruitment profile for the treatment of allergy.
Thus, we investigated whether a lower dose of bisdionin F would
allow effects on neutrophil and eosinophil cell numbers to be
segregated. The lowest dose at which we could observe any chi-
tinase inhibition was 1 mg/kg, and thus allergic animals were
treated with 1 and 5 mg/kg of bisdionin F and eosinophil and
neutrophil recruitment was assessed (Figure 4A). Increases in
eosinophilia of OVA-challengedmice were reduced by treatment
with both 1 and 5mg/kg dose. However, at both doses, bisdionin
F treatment also resulted in a significant 2- to 4-fold increase in
neutrophil cell number. A bronchoconstrictor, methacholine,
was administered following challenge with OVA or PBS to
measure penH (enhanced pause), a measurement that reflects
changes to ventillatory function in spontaneously breathing
mice, as described in detail in the Experimental Procedures.
As expected, penHwas significantly increased in vehicle-treated
allergic animals compared to naive animals (p < 0.001, Fig-
ure 4C). A dose of 5 mg/kg bisdionin F had no effect on penH
measurements in PBS-challenged animals (data not shown).
However, bisdionin F treatment significantly reduced penH in
allergic mice at both 1 and 5 mg/kg at the highest concentration
of methacholine used.572 Chemistry & Biology 18, 569–579, May 27, 2011 ª2011 ElsevierExpression of Genes Associated with Tissue
Remodeling Are Altered by Chitinase Inhibition
It has been suggested that chitinases play a role in tissue remod-
eling responses in models of infection and Th2-driven inflamma-
tion (reviewed in Lee 2009) with eosinophils also implicated in
remodeling. We thus predicted that chitinase inhibition, leading
to reduced eosinophilia, might have beneficial effects on the
expression of genes associated with lung remodeling. Contrary
to our expectation, the expression of genes associated with
remodeling including procollagen I, matrix-metalloprotease-12
(MMP-12), and Ym1 (chitinase-like protein) were significantly
increased in bisdionin F-treated animals, while the tissue inhib-
itor of metalloproteinases 1 (TIMP-1) was downregulated
(Figures 5A-D). Furthermore, the ratio of MMP:TIMP expression
was enhanced 2.5 fold following bisdionin F treatment, suggest-
ing enhanced MMP activity is likely (Figure 5E).DISCUSSION
The therapeutic targeting of chitinase enzymatic activity was
proposed when it was discovered that AMCase is highly ex-
pressed in both animal models of allergic inflammation and in
human asthmatics (Bierbaum et al., 2005; Zhu et al., 2004) and
that nonspecific inhibition of chitinases had anti-inflammatory
effects (Matsumoto et al., 2009; Zhu et al., 2004). However, the
inhibitors used in these studies are not specific for AMCase
and do not provide tangible starting points for the development
of such compounds.With the aid of hAMCase structural data, we
undertook the design of a selective hAMCase inhibitor that
would allow us to more precisely dissect the role of AMCase in
allergic inflammation. The design strategy for the novel chitinase
inhibitor bisdionin F demonstrates that selective inhibitors of
AMCase activity can be synthesized and as shown here, used
in vivo to examine the function of AMCase during Th2-driven
allergic inflammation. Importantly, our findings suggest that
key properties of AMCase may have been overlooked using
broad chitinase inhibitors.
Bisdionin F showed micromolar affinity against recombinant
mAMCase in vitro and reduced both the increased lung chitinase
enzymatic activity induced by allergic OVA challenge and the
basal level of chitinase activity in naive mice. Treatment with
bisdionin F significantly reduced eosinophil cell numbers in the
lavage of allergic mice, an effect that has been previously
described for other chitinase inhibitors (Matsumoto et al.,Ltd All rights reserved
Table 1. Summary of Data Collection and Structure Refinement
Statistics for the hAMCase-Bisdionin C and F Complexes
hAMCase
+ bisdionin C
hAMCase
+ bisdionin F
Resolution (A˚) 20-2.20
(2.25-2.20)
20-2.25
(2.33-2.25)
Cell dimensions (A˚) 145.21 149.07
152.08
144.78 149.19
151.28
Number of unique
reflections
161985 154470
Multiplicity 4.3 4.1
Rmerge (%) 10.1 (69.6) 9.6 (57.7)
I/s(I) 14.1 (2.7) 14.8 (2.7)
Completeness (%) 99.9 (99.9) 99.6 (99.8)
Number of atoms in
refinement
19339 19347
Number of solvent
molecules
1057 1119
Rwork (%) 18.1 17.3
Rfree (%) 22.8 21.9
Average protein
B-factor (A˚2)
31.3 28.5
Average ligand
B-factor (A˚2)a
42.0 22.6
Average solvent
B-factor (A˚2)
31.5 29.7
Rmsd bond lengths (A˚) 0.022 0.023
Rmsd bond angels () 1.86 1.89
Ramachandran plot
statistics (%)
Residues in favored
regions
97.7 98.0
Residues in allowed
regions
2.1 2.0
Residues in outlier
regions
0.1 0.0
Values for the highest resolution shell are shown in parenthesis.
aCalculated from ligand molecules occupying the 1 and 3 subsites.
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Chemical Dissection of AMCase Function2009; Zhu et al., 2004). Although the central role of eosinophils in
the allergic reaction is sometimes debated, reduced eosinophil
numbers are associated with improvements in ventilatory func-
tion and tissue remodeling (Flood-Page et al., 2003; Humbles
et al., 2004). In this current study, chitinase inhibition decreased
penH in allergic animals at doses in which eosinophil recruitment
was reduced by approximately 50%, supporting the notion that
eosinophils regulate ventilatory function.
The most striking and consistent feature of bisdionin F treat-
ment was the neutrophil recruitment observed in OVA-chal-
lenged mice but not control PBS-challenged mice. While not
considered a classical inflammatory mediator in Th2-driven
allergy, neutrophils have increasingly and controversially been
placed in the spotlight as important mediators of persistent
and corticosteroid-resistant asthma (Green et al., 2002; Jataka-
non et al., 1999). Recent studies have correlated chronic asthma
severity with the numbers of neutrophils in the sputum andChemistry & Biology 18,bronchial biopsies (Louis et al., 2000; Woodruff et al., 2001)
with neutrophil recruitment and activation mediated largely by
IL-8 (Monteseirin 2009). Bisdionin F-induced neutrophilia was
accompanied by an increase in MIP-1a secretion and expres-
sion, both at the site of inflammation and the draining lymph
nodes. Although the role of MIP-1a during allergic asthma has
been described to a lesser extent than IL-8, the levels of
MIP-1a are increased in lavage fluid from allergic asthmatics
(Alam et al., 1996) and hence may be an important component
for induction of neutrophil chemotaxis. In addition to increased
neutrophil numbers following bisdionin F treatment, we
observed alterations in airway remodeling genes that would be
predicted to have negative consequences for lung function.
Whether these changes were the result of the altered eosino-
phil/neutrophil balance or a more direct effect of the inhibitor
remains to be determined.
Treatmentwith demethylallosamidin did not result in neutrophil
recruitment in allergic mice (Matsumoto et al., 2009), while the
effects of allosamidin and anti-AMCase sera on neutrophil cell
number were not reported (Zhu et al., 2004). Bisdionin F-induced
neutrophilia does correlate well with the inhibition of chitinase
activity. Furthermore, in previous work, the potential side effects
of xanthine-based (bisdionin) chitinase inhibitors were explored
by monitoring phosphodiesterase inhibition, a known target of
xanthine derivatives (Rao et al., 2005). Results showed that as
larger substituents were added to the N1 position of the xanthine
structure, selectivity for the chitinases increased. Bisdionin F is
further extended at this position, reducing the likelihood of off-
target effects, although these cannot be fully excluded. Bisdionin
F-induced neutrophilia could be mediated, at least in part,
through chitin accumulation in the lungs. Chitin has been shown
to induce inflammatory cell recruitment (Reese et al., 2007),
including neutrophils (Da Silva et al., 2008). While these immuno-
logical actions of chitin would normally be limited in mammals by
chitinase-mediated chitin degradation, interference with chiti-
nase enzymatic activity would likely result in chitin accumulation.
Because bisdionin F exhibits selectivity for AMCase, unlike allo-
samidin, which is more effective at inhibiting CHIT1 (Boot et al.,
2001; Zheng et al., 2005), the activity of CHIT1 in the lung should
remain largely unaffected. Both CHIT1 and AMCase may be
required to ensure full degradation and clearance of chitin. The
level of chitinase activity in the lung and the predominance of
one enzyme over the other may influence the size and quantity
of chitin degradation products, which has been shown to deter-
mine the inflammatory outcome (Da Silva et al., 2008). Impor-
tantly, if the ability of AMCase to break down chitin is important,
the absence of neutrophils in PBS-challenged mice treated with
bisdionin F suggests that other factors are at play and that an
actively primed immune environment is required for chitin to
induce neutrophilia.
In addition to inhibiting chitinase activity (Matsumoto et al.,
2009; Zhu et al., 2004), AMCase has been targeted by RNA inter-
ference (Yang et al., 2009) and anti-AMCase-sera (Zhu et al.,
2004). The overlap of all three treatments appears to be a reduc-
tion in eosinophilia, also observed with bisdionin F. Approaches
that more specifically targeted AMCase yielded additional
effects not seen with broad chitinase inhibitors, including reduc-
tion of IL-13-induced chemotactic factors, antigen-specific IgE
responses, and airway hyperresponsiveness. Also consistent569–579, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 573
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Figure 3. Inhibition of Allergen-Induced Lung Chitinase Activity and Changes to Cell Recruitment in Lavage and Lung Tissue
(A) Chitinase activity measured in lung homogenates from PBS/OVA-challenged mice treated with vehicle or bisdionin F. Bisdionin F reduced chitinase activity
(expressed as 4MU substrate hydrolysed/hr/mg of lung tissue) in both PBS-challenged and OVA-challenged mice.
(B and C) Total cell number (B) and differential cell counts (C) of macrophages, lymphocytes, neutrophils, and eosinophils in bronchoalveolar lavage from bis-
dionin F and vehicle treated PBS and OVA-challenged mice.
(D) Representative H&E stained lung sections (i) Vehicle PBS-challenged mice, (ii) bisdionin F PBS-challenged mice, (iii) vehicle OVA-challenged mice, and (iv)
bisdionin F OVA-challenged mice. Magnification, 3400.
(E) Representative H&E stained lung sections from a second independent experiment; (i) vehicle OVA-challenged mice and (ii) bisdionin F OVA-challenged mice.
Magnification, 3200.
(F) Representative lung sections stained with naphthol AS-D choloracetate esterase showing (i) vehicle OVA-challenged mice or (ii) bisdionin F OVA-challenged
mice. Neutrophils exhibit red staining; cell nuclei stained with hematoxylin. Magnification, 3400.
(G) Protein levels of MIP-1a in supernatant of tLN cells from PBS or OVA-challenged mice, cultured in RPMI or OVA antigen (0.5 mg/mL) for 72 hr.
(H) Expression of MIP-1a mRNA from lung of PBS and OVA-challenged mice, normalized to the level of housekeeping gene, GAPH, in individual lung samples.
Chitinase inhibitor, bisdionin F, 5 mg/kg i.p., n = 5–7 per group. NS, not significant. *p < 0.05, **p < 0.01, and ***p < 0.001 compared to vehicle PBS; #p < 0.01,
##p < 0.01, ###p < 0.001. Data is representative of three individual experiments.
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Figure 4. Treatment with Two Different
Doses of Bisdionin F during Allergic Inflam-
mation
(A) Eosinophil and neutrophil cell numbers in the
bronchoalveolar lavage from chitinase inhibitor
treated allergic mice compared to vehicle treat-
ment.
(B) Chitinase activity measured in lung homoge-
nates from OVA-challenged mice treated.
(C) Relationship of chitinase inhibition on ventila-
tory function in allergic animals. PenH values were
measured in conscious, unrestrained mice
administered with increasing doses of an aero-
solized bronchoconstrictor, methacholine.
Vehicle-treated PBS-challenged mice, open
squares; Vehicle-treated OVA-challenged mice,
closed squares; 1 mg/kg bisdionin F OVA-chal-
lenged, open circles; 5 mg/kg bisdionin F, closed
circles, dashed line. Chitinase inhibitor, bisdionin F
1 and 5mg/kg, i.p.; n = 5–6mice per group. NS, not
significant. **p < 0.01 and ***p < 0.001 compared
to vehicle PBS and #p < 0.05 and ##p < 0.01
compared to vehicle OVA-challenged mice.
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neutrophils in animals infected with an adenoviral expressing
short hairpin RNA (shRNA) against AMCase relative to mice
that received a shRNA control (Yang et al., 2009). Both anti-
AMCase and shRNA treatment are likely to have influenced
protein levels and thus will not solely have addressed the role
of AMCase enzymatic activity.
These studies, along with the findings presented here, empha-
size the importance of generating specific tools for dissecting the
role of chitinases during Th2-driven allergic inflammation. A
recent study has developed high-throughput-, fragment-, and
virtual-based screening methods to identify a selective inhibitor
of AMCase activity (Cole et al., 2010). The study demonstrated
inhibition of chitinase activity in vivo, albeit, at a much greater
dosing regime (50 mg/kg twice daily) compared to bisdionin F,
but did not investigate the immunological or physiological
consequences. We have used both structural and enzyme
inhibition data to successfully design bisdionin F and utilized
this compound in vivo to selectively inhibit AMCase chitinolytic
activity during allergic airway inflammation. While our study
has raised important questions regarding the therapeutic
benefit of chitinase inhibition for the treatment of Th2-driven
inflammatory conditions, bisdionin F is a valuable tool for under-
standing the yet unknown functions of AMCase. Further, studies
in which the active site Asp138 has been mutated to Ala have
demonstrated distinct enzyme-dependent and -independent
properties for AMCase that can both be blocked by allosamidin
(Hartl et al., 2009). Thus, development of therapeutically useful
inhibitors may still be possible, based on further refinement ofChemistry & Biology 18, 569–579, May 27, 2011the bisdionins in conjunction with a better
understanding of both the chitinases
and CLPs, some of which, like mutant
AMCase, can still bind chitin (and thus
presumably chitinase inhibitors), but
cannot cleave it (Hartl et al., 2009; Mo-
hanty et al., 2009).The active chitinases are highly conserved across mammals,
while the CLPs represent more recent gene duplication events
with subsequent loss-of-function mutations (Bussink et al.,
2007). This has resulted in an intriguing situation in which all
mammalsexpress thehighlyconservedactiveenzymeschitotrio-
sidase and AMCase but additionally express a broad range of
diverse CLPswithout known function. The data presented herein
have alreadydemonstrated novel inhibitory effects of AMCase on
neutrophil recruitment potentially through MIP-1a signaling.
Intriguingly, following the direct transfection of Ym1 (a murine
CLP) into the lungs of naive mice, we have observed neutrophil
recruitment and enhanced MIP-1a secretion (data not shown).
Thus, enhanced Ym1 expression following bisdionin F treatment
(Figure 5A) may explain the increases inMIP-1a and neutrophilia.
This raises the exciting possibility that chitinases and CLPs have
cross-regulatory properties. Further, the dissection of the differ-
ential roles of this expanded gene family may lead to future
combination therapies in which both eosinophilia and neutro-
philia can be repressed for the successful treatment of allergies.
Although mouse CLPs cannot fully represent the human
proteins, the evolutionary principles driving the remarkably rapid
divergence of CLPs are likely to be shared across species. Thus
studies inmice should allow us to address fundamental functional
differences between chitinases and CLPs. Indeed, the potential
capacity of broad chitinase inhibitors such as allosamidin to bind
a range of CLPs may have previously obscured AMCase-specific
activities. It is only through the use of selective chemical tools like
the bisdionins that we can begin to unravel the complex mecha-
nistic and regulatory pathways of chitinase and CLP functions.ª2011 Elsevier Ltd All rights reserved 575
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Figure 5. Chitinase Inhibition Alters the Expression
of Tissue Remodeling Genes
(A–D) Chitinase inhibition alters the expression of genes
implicated in lung tissue remodeling. mRNA expression of
(A) Ym1, (B) pro-collagen I, (C) TIMP-1, and (D) MMP-12
were measured in RNA extracted from lung tissue of
PBS-challenged animals or vehicle and bisdionin
F-treated allergic animals.
(E) The ratio of MMP-12:TIMP-1 mRNA expression.
Chitinase inhibitor, bisdionin F, 1 and 5 mg/kg i.p.; n = 5–6
mice per group. *p < 0.05, **p < 0.01, and ***p < 0.001
compared to vehicle PBS-challenged mice; #p < 0.05 and
###p < 0.001 compared to vehicle OVA-challenged mice.
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Chitotriosidase (CHIT1) and acidic mammalian chitinase
(AMCase) are mammalian chitinases found in the lung and
are upregulated during innate and adaptive immune
responses, respectively. AMCase has previously been iden-576 Chemistry & Biology 18, 569–579, May 27, 2011 ª2011 Elsevier Ltd All rights resetified as a mediator in allergic inflammation
and asthma, although most information
regarding AMCase function has been
provided through studies using allosamidin,
a nonspecific inhibitor of family 18
chitinases. To address the role of AMCase
during Th2-driven inflammation, we used
a rational approach to design a selective
inhibitor of AMCase chitinase activity, bis-
dionin F. Bisdionin F showed in vivo efficacy
in a murine model of allergic inflammation
and, similar to allosamidin, attenuated lung
chitinase activity, reduced eosinophil influx,
and improved ventilatory function. However,
our studies with bisdionin F reveal functions
of AMCase that have previously gone
unreported, likely due to the unspecific
nature of other chitinase inhibitors. Neutro-
phils, while not typically associated with
a Th2-allergic response, were strikingly
enhanced with AMCase inhibition. While
such results question the therapeutic poten-
tial of bisdionin F monotherapy and, indeed,
other chitinase inhibitors for Th2-inflamma-
tory conditions, it does not preclude the
possibility to design AMCase inhibitors with
appropriate actions. For example, beneficial
effects of allosamidin and bisdionin F may
be due to actions that are independent of
direct chitinase activity. This same class of
inhibitor could potentially be developed
with activity against chitinase-like proteins
(CLPs) without affecting chitinase activity.
Thus, an understanding of the actions of
the highly diverse CLP family, which are
also upregulated during Th2-driven condi-
tions, as well as enzyme-independent
actions of AMCase, warrants urgent atten-tion. Overall, the approach of designing a specific class of
inhibitor that shows selectivity for AMCase has provided
an invaluable tool to begin dissecting the function of AM-
Case during pathology and has already alluded to the poten-
tial of cross-regulatory actions of the chitinase and CLP
family members.rved
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Bisdionin Synthesis
Bisdionin C (Itahara and Imamura 1994), with an alkyl linker of three methylene
units, was synthesized as previously described (Schuttelkopf et al., 2011).
Bisdionin F was prepared according to the method of Allwood et al. (Allwood
et al., 2007) by the alkylation of 1-(3-bromopropyl)-3, 7-dimethyl-1H-purine-
2,6(3H, 7H)-dione (Fischer et al., 1999) with 7-(4-methoxybenzyl)-3-methyl-
1H-purine-2,6(3H, 7H)-dione (Sakai et al., 1992), followed by removal of the
4-methoxybenzyl group under acidic conditions (Sakai et al., 1992).
Compounds were characterized by 1H and 13C NMR and HRMS and revealed
no trace contamination by high molecular weight species such as LPS. Purity
was > 95% as judged by analytical HPLC.
Protein Expression, Crystallization, and Structure Determination
of hAMCase Complexes
A fragment corresponding to hAMCase 22-398 (bp 64–1194) was ligated into
the pPIC9 vector (Invitrogen) using the Xho I and Not I restriction sites. The
enzyme was subsequently overexpressed as a secreted protein from the
Pichia pastoris GS115 strain and purified using a combination of affinity chro-
matography and size-exclusion chromatography. Pure hAMCase was spin
concentrated to 37 mg/ml in 25 mM HEPES (pH 6.8), 250 mM NaCl. The
protein was crystallized at 30C from 75% saturated NaCl, 0.1 M HEPES
(pH 7.4) using the hanging drop method. Crystals grew to an approximate
size of 200 3 100 3 50 mm. Crystals were cryoprotected in 50% saturated
NaCl, 20% glycerol in 0.1 M HEPES (pH 7.4) and subsequently flash frozen
in liquid nitrogen. The binary complexes were formed by soaking crystals in
reservoir solution containing saturated concentrations of bisdionin C (4 hr)
and bisdionin F (2 hr) prior to cryoprotection. Data for hAMCase were
collected at ID14-EH1 at the European Synchrotron Radiation Facilities
(ESRF) using a cryostream of cold nitrogen (110 K). Processing and scaling
were done using the HKL suite of programs (Otwinowski and Minor 1997).
Initial phases were obtained by molecular replacement using MOLREP
(Vagin and Teplyakov 1997) with the crystal structure of hCHIT1 as a search
model (PDB entry 1LG2; Fusetti et al., 2002). Cross-validation (Kleywegt and
Brunger 1996) was applied by excluding 1% of the reflections throughout the
refinement procedure. Rigid body and simulated annealing followed by
several rounds of combined refinement (energy minimization and B-factor
refinement) using strict noncrystallographic symmetry were done using
CNS (Brunger et al., 1998). The graphical program O (Jones et al., 1991)
combined with density modification including density averaging from the
CCP4 program suite (Collaborative Computational Project 1994) was used
for manual adjustments of the structures, and water molecules were included
as oxygen atoms after each round of combined refinement using appropriate
criteria. Refmac5 (Murshudov et al., 1997) was used in latter stages of
refinement. hAMCase crystallized in space group P212121, and the final
models contain six monomers each consisting of 377 residues per protein
monomer. The overall fold of the six monomers are similar, with rmsd values
(Ca atoms) of 0.21–0.32 A˚ upon superposition. In the interest of simplicity,
the structures are discussed consistently using the first monomer in the
coordinate files. Topologies for ligands were obtained using the PRODRG
server (Schuttelkopf and van Aalten 2004) and ligands were included using
unbiased Fo-Fc, fcalc electron density maps.
Generation of AMCase-Expressing Stable Cell Lines
The full-length-coding region of mAMCase was amplified using a lung cDNA
template. The cDNA fragment was directionally cloned into pcDNA3.1 (Invitro-
gen), to generate a V5/His tagged plasmid. TOP10 competent cells were
transformed with the AMCase plasmid and sequence confirmed. Mammalian
COS-7 cells were transfected with AMCase-pcDNA3.1 plasmid using
Lipofectamine 2000 (Invitrogen). COS-7 cell supernatants were screened for
AMCase protein by western blot and chitinase activity. A stable AMCase-
expressing cell line was generated using G418 selection medium (RPMI).
Chitinase Activity Assay
Chitinase activity of hAMCase, lung homogenates, or AMCase COS-7 cell
supernatants (serum-free) were determined using 4-methylumbelliferyl-b-D-
N,N0,N00-triacetylchitotrioside and 4-methylumbelliferyl-b-D-N,N0,N00-triacetyl-Chemistry & Biology 18,chitobioside, as described. Samples were incubated with substrate
(0.022 mM in 100 mM citric acid, 200 mM sodium phosphate buffer [pH 5.2])
in a final volume of 50 mL. After a 10 min incubation at 37C, the reaction
was stopped with the addition of 500 ml sodium carbonate buffer (0.5 M
sodium carbonate and 0.5 M sodium bicarbonate [pH 10.6]). Liberated
4-methlyumberlliferone was quantified using a microplate fluorometer (excita-
tion 360 nm/emission 440 nm). Ki and IC50 values were determined in the
presence of different concentrations of inhibitor. Experiments were performed
in duplicate or triplicate.
OVA Sensitization and Challenge
All experiments used female BALB/c mice, 6- to 8-weeks-old. Mice were kept
in individually ventilated cages and all experiments were conducted under UK
Home Office guidelines. Mice were sensitized (day 0) and boosted (day 14) i.p.
with 20 mg OVA (Grade V, Sigma) adsorbed to 9% potassium alum. Mice
were either challenged on day 28 and 30 with 50 mg OVA or PBS by the intra-
tracheal route or were challenged with 1% OVA or PBS by aerosol for 30 min
on day 28 to day 30. Bisdionin F or vehicle (2% DMSO in PBS) was adminis-
tered i.p. 2 hr prior to each challenge at doses indicated in the text. Necropsies
were performed 24 hr after the final airway challenge.
Ventilatory Function
On day 30, prior to the final OVA challenge and bisdionin F dose, ventilatory
function (enhanced pause [penH]) was measured using unrestrained whole-
body plethysmography (Buxco Systems) and analyzed with system XA soft-
ware (Buxco Electronics) as previously described (Hamelmann et al., 1997).
Briefly, conscious mice were placed in individual chambers for a 10 min accli-
matization period. Spontaneous breathing patterns in mice relate to changes
in chamber air pressure, which are measured by a transducer attached to
the chamber wall. Differences in the rates of pressure change during peak
inspiration and peak expiration and the timing of expiration are used to calcu-
late penH according to the following equation; penH = ((expiratory time/relax-
ation time) – 1) 3 (peak expiratory flow (mL/s)/peak inspiratory flow (ml/s)).
PenH measurements are not used as a quantitative measurement that relates
to airway size and rather reflect changes to ventilation following bronchocon-
striction. Baseline measurements of penH were made following an aerosol of
PBS. Doubling doses ofmethacholine (3.125/50mg/mL in PBS, Sigma) were
aerosolized for 2 min followed by 5 min data collection. PenH measurements
were averaged for the entire dose period.
Bronchoalveolar Lavage
Approximately 24 hr after the last challenge, mice were killed, the trachea
cannulated, and internal airspaces lavaged with 400 ml 0.25% BSA in PBS
followed by three 300 ml washes. Total cell numbers were counted and
cytospins prepared for differential cell counts, which were assessed by
morphology following Diff Quick staining (Reagena). BALF was centrifuged
at 1200 3 g and supernatant stored at 20C for further analysis.
Lung Protein Homogenates
Protein from dissected lung was homogenized (TissueLyser, QIAGEN) in lysis
buffer containing protease cocktail inhibitor (Sigma). Samples were incubated
for 20 min on ice, prior to centrifugation 10,000 3 g to removed cell debris.
Protein amounts were quantified with Coomassie (Bradford) Reagent. Homog-
enates were stored at 70C for use in the chitinase activity assay.
Histology
Following BAL, the right lobe of the lung was fix-perfused with 4% formalde-
hyde and subsequently processed to paraffin and embedded. Standard H&E
staining was performed to assess gross pathology and lung neutrophils
were visualized by naphthol AS-D choloracetate esterase staining (Sigma).
RNA Extraction and Quantitative Real-Time PCR
One part of the left lobe of the lung, removed following BALF, was stored
in RNAlater (Ambion) at 4C for up to 4 weeks. Lung samples were homoge-
nized in RLT lysis buffer using TissueLyser (QIAGEN) and total RNA extracted
using RNeasy mini spin columns (QIAGEN). RNA (1 mg) was used for synthesis
of cDNA using Moloney murine leukemia virus reverse transcriptase. Relative
quantification of genes was carried out by RT-PCR using the Roche569–579, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 577
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Chemical Dissection of AMCase FunctionLightcycler, as previously described (Nair et al., 2005). PCR amplication was
analyzed using 2nd derivative Maximum alogarithm (LightCycler 480 SW 1.5,
Roche) and the expression of the gene of interest was normalized to the house-
keeping gene, GAPDH. Primer sequences used were as follows: GAPDH-For
ATGACATCAAGAAGGTGGTG, Rev CATACCAGGAAATGAGCTTG; Ym1-For
TCACAGGTCTGGCAATTCTTCTG, Rev TTGTCCTTAGGAGGGCTTCCTC;
Pro Collagen I-For AACTGGACTGTCCCAACCCC, Rev TCCCTCGACTCCTA
CATCTTCTG; MIP-1a-For TGCCCTTGCTGTTCTTCTCT, Rev GTGGAATC
TTCCGGCTGTAG; MMP-12-For CAATTGGAATATGACCCCCTGT, Rev AG
CAAGCACCCTTCACTACAT; and TIMP-1-For GTGGGAAATGCCGCAGAT,
Rev GGGCATATCCACAGAGGCTTT.
Cytokine and Chemokine Secretion from Draining Lymph Node Cell
Cultures
The draining thoracic lymph nodes (tLN) were dissected and single-cell
suspensions made before being plated out at 1 3 106 cells/mL in 96-well
plates (RPMI 1640 supplemented with L-glutamine, penicillin streptomycin,
and FCS). Cells were stimulated with 500 mg/mL OVA and incubated for
72 hr at 37C, 5%CO2. MIP-1a levels were measured in cell-free supernatants
using a Luminex kit (Invitrogen) and samples were read with a Luminex 100
multiplex bead array system.
Statistical Analysis
Data are expressed as the mean ± standard error of the mean, with individual
numbers indicated for each experiment. Statistical analysis was performed
with PRISM 4.0 (Graphpad Software). Differences between groupswere deter-
mined using a one-way ANOVA with Dunnetts post-hoc test. A p < 0.05 was
considered a significant difference.
ACKNOWLEDGMENTS
We would like to thank S. Duncan (University of Edinburgh) for her technical
assistance with the murine model of allergic inflammation and S. Jenkins
and D. Ru¨ckerl for helpful discussions. This work was supported by Asthma
UK, the Medical Research Council UK, and the Wellcome Trust. The authors
declare no competing financial interests.
Received: November 15, 2010
Revised: February 21, 2011
Accepted: February 28, 2011
Published: May 26, 2011
REFERENCES
Alam, R., York, J., Boyars, M., Stafford, S., Grant, J.A., Lee, J., Forsythe, P.,
Sim, T., and Ida, N. (1996). Increased MCP-1, RANTES, and MIP-1alpha in
bronchoalveolar lavage fluid of allergic asthmatic patients. Am. J. Respir.
Crit. Care Med. 153, 1398–1404.
Allwood, M.B., Cannan, B., van Aalten, D.M., and Eggleston, I.M. (2007).
Efficient synthesis of 1,3,7-substituted xanthines by a safety-catch protection
strategy. Tetrahedron 63, 12294–12302.
Barone, R., Simpore, J., Malaguarnera, L., Pignatelli, S., and Musumeci, S.
(2003). Plasma chitotriosidase activity in acute Plasmodium falciparum
malaria. Clin. Chim. Acta 331, 79–85.
Berecibar, A., Grandjean, C., and Siriwardena, A. (1999). Synthesis and
Biological Activity of Natural Aminocyclopentitol Glycosidase Inhibitors:
Mannostatins, Trehazolin, Allosamidins, and Their Analogues. Chem. Rev.
99, 779–844.
Bierbaum, S., Nickel, R., Koch, A., Lau, S., Deichmann, K.A., Wahn, U.,
Superti-Furga, A., and Heinzmann, A. (2005). Polymorphisms and haplotypes
of acid mammalian chitinase are associated with bronchial asthma. Am. J.
Respir. Crit. Care Med. 172, 1505–1509.
Boot, R.G., Blommaart, E.F., Swart, E., Ghauharali-van der Vlugt, K., Bijl, N.,
Moe, C., Place, A., and Aerts, J.M. (2001). Identification of a novel acidic
mammalian chitinase distinct from chitotriosidase. J. Biol. Chem. 276, 6770–
6778.578 Chemistry & Biology 18, 569–579, May 27, 2011 ª2011 ElsevierBoot, R.G., Bussink, A.P., Verhoek, M., de Boer, P.A., Moorman, A.F., and
Aerts, J.M. (2005). Marked differences in tissue-specific expression of chiti-
nases in mouse and man. J. Histochem. Cytochem. 53, 1283–1292.
Brameld, K.A., Shrader, W.D., Imperiali, B., and Goddard, W.A., 3rd. (1998).
Substrate assistance in the mechanism of family 18 chitinases: theoretical
studies of potential intermediates and inhibitors. J. Mol. Biol. 280, 913–923.
Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-
Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al.
(1998). Crystallography & NMR system: A new software suite for macromolec-
ular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905–921.
Bussink, A.P., Speijer, D., Aerts, J.M., and Boot, R.G. (2007). Evolution of
Mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics
177, 959–970.
Cole, D.C., Olland, A.M., Jacob, J., Brooks, J., Bursavich, M.G., Czerwinski,
R., DeClercq, C., Johnson, M., Joseph-McCarthy, D., Ellingboe, J.W., et al.
(2010). Identification and characterization of acidicmammalian chitinase inhib-
itors. J. Med. Chem. 53, 6122–6128.
Collaborative Computational Project. (1994). The CCP4 suite: programs for
protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760–763.
Da Silva, C.A., Hartl, D., Liu, W., Lee, C.G., and Elias, J.A. (2008). TLR-2 and
IL-17A in chitin-induced macrophage activation and acute inflammation.
J. Immunol. 181, 4279–4286.
Fischer, B., Yefidoff, R., Major, D.T., Rutman-Halili, I., Shneyvays, V., Zinman,
T., Jacobson, K.A., and Shainberg, A. (1999). Characterization of ‘‘mini-nucle-
otides’’ as P2X receptor agonists in rat cardiomyocyte cultures. An integrated
synthetic, biochemical, and theoretical study. J. Med. Chem. 42, 2685–2696.
Flood-Page, P.T., Menzies-Gow, A.N., Kay, A.B., and Robinson, D.S. (2003).
Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes
numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167, 199–204.
Fusetti, F., vonMoeller, H., Houston, D., Rozeboom, H.J., Dijkstra, B.W., Boot,
R.G., Aerts, J.M., and van Aalten, D.M. (2002). Structure of human chitotriosi-
dase. Implications for specific inhibitor design and function of mammalian chi-
tinase-like lectins. J. Biol. Chem. 277, 25537–25544.
Green, R.H., Brightling, C.E., Woltmann, G., Parker, D., Wardlaw, A.J., and
Pavord, I.D. (2002). Analysis of induced sputum in adults with asthma: identi-
fication of subgroup with isolated sputum neutrophilia and poor response to
inhaled corticosteroids. Thorax 57, 875–879.
Hamelmann, E., Schwarze, J., Takeda, K., Oshiba, A., Larsen, G.L., Irvin, C.G.,
and Gelfand, E.W. (1997). Noninvasive measurement of airway responsive-
ness in allergic mice using barometric plethysmography. Am. J. Respir. Crit.
Care Med. 156, 766–775.
Hartl, D., He, C.H., Koller, B., Da Silva, C.A., Kobayashi, Y., Lee, C.G., Flavell,
R.A., and Elias, J.A. (2009). Acidic mammalian chitinase regulates epithelial
cell apoptosis via a chitinolytic-independent mechanism. J. Immunol. 182,
5098–5106.
Humbles, A.A., Lloyd, C.M., McMillan, S.J., Friend, D.S., Xanthou, G.,
McKenna, E.E., Ghiran, S., Gerard, N.P., Yu, C., Orkin, S.H., et al. (2004).
A critical role for eosinophils in allergic airways remodeling. Science 305,
1776–1779.
Itahara, T., and Imamura, K. (1994). Preparation and NMR Study of 7,70-
(a,u-Alkanediyl)bis[theophylline], 1,10-(a,u-Alkanediyl)bis[theobromine], and
1,10-(a,u-Alkanediyl)bis. Bull. Chem. Soc. Jpn. 67, 7.
Jatakanon, A., Uasuf, C., Maziak, W., Lim, S., Chung, K.F., and Barnes, P.J.
(1999). Neutrophilic inflammation in severe persistent asthma. Am. J. Respir.
Crit. Care Med. 160, 1532–1539.
Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. (1991). Improved
methods for building protein models in electron density maps and the location
of errors in these models. Acta Crystallogr. A 47, 110–119.
Kleywegt, G.J., and Brunger, A.T. (1996). Checking your imagination: applica-
tions of the free R value. Structure 4, 897–904.
Labadaridis, I., Dimitriou, E., Theodorakis, M., Kafalidis, G., Velegraki, A., and
Michelakakis, H. (2005). Chitotriosidase in neonates with fungal and bacterial
infections. Arch. Dis. Child. Fetal Neonatal Ed. 90, F531–F532.Ltd All rights reserved
Chemistry & Biology
Chemical Dissection of AMCase FunctionLee, C.G. (2009). Chitin, chitinases and chitinase-like proteins in allergic
inflammation and tissue remodeling. Yonsei Med. J. 50, 22–30.
Louis, R., Lau, L.C., Bron, A.O., Roldaan, A.C., Radermecker, M., and
Djukanovic, R. (2000). The relationship between airways inflammation and
asthma severity. Am. J. Respir. Crit. Care Med. 161, 9–16.
Matsumoto, T., Inoue,H.,Sato,Y., Kita,Y.,Nakano, T.,Noda,N.,Eguchi-Tsuda,
M., Moriwaki, A., Kan, O.K., Matsumoto, K., et al. (2009). Demethylallosamidin,
a chitinase inhibitor, suppresses airway inflammation and hyperresponsive-
ness. Biochem. Biophys. Res. Commun. 390, 103–108.
Mohanty, A.K., Fisher, A.J., Yu, Z., Pradeep, M.A., Janjanam, J., and Kaushik,
J.K. (2009). Cloning, expression, characterization and crystallization of BRP39,
a signalling glycoprotein expressed during mammary gland apoptosis. Protein
Expr. Purif. 64, 213–218.
Monteseirin, J. (2009). Neutrophils and asthma. J. Investig. Allergol. Clin.
Immunol. 19, 340–354.
Murshudov, G.N., Vagin, A.A., and Dodson, E.J. (1997). Refinement of macro-
molecular structures by the maximum-likelihood method. Acta Crystallogr. D
Biol. Crystallogr. 53, 240–255.
Nair, M.G., Gallagher, I.J., Taylor, M.D., Loke, P., Coulson, P.S., Wilson, R.A.,
Maizels, R.M., and Allen, J.E. (2005). Chitinase and Fizz family members are
a generalized feature of nematode infection with selective upregulation of
Ym1 and Fizz1 by antigen-presenting cells. Infect. Immun. 73, 385–394.
Olland, A.M., Strand, J., Presman, E., Czerwinski, R., Joseph-McCarthy, D.,
Krykbaev, R., Schlingmann, G., Chopra, R., Lin, L., Fleming, M., et al. (2009).
Triad of polar residues implicated in pH specificity of acidic mammalian chiti-
nase. Protein Sci. 18, 569–578.
Otwinowski, Z., and Minor, W. (1997). Processing of X-ray Diffraction Data
Collected in Oscillation Mode. Methods Enzymol. 276, 307–326.
Rao, F.V., Andersen, O.A., Vora, K.A., Demartino, J.A., and van Aalten, D.M.
(2005). Methylxanthine drugs are chitinase inhibitors: investigation of inhibition
and binding modes. Chem. Biol. 12, 973–980.
Reese, T.A., Liang, H.E., Tager, A.M., Luster, A.D., Van Rooijen, N.,
Voehringer, D., and Locksley, R.M. (2007). Chitin induces accumulation in
tissue of innate immune cells associated with allergy. Nature 447, 92–96.
Sakai, R., Konno, K., Yamamoto, Y., Sanae, F., Takagi, K., Hasegawa, T.,
Iwasaki, N., Kakiuchi, M., Kato, H., and Miyamoto, K. (1992). Effects of alkyl
substitutions of xanthine skeleton on bronchodilation. J. Med. Chem. 35,
4039–4044.
Sakuda, S., Isogai, A., Matsumoto, S., Suzuki, A., and Koseki, K. (1986). The
structure of allosamidin, a novel insect chitinase inhibitor produced by
Streptomyces sp. Tetrahedron Lett. 27, 2475–2478.
Schuttelkopf, A.W., Andersen, O.A., Rao, F.V., Allwood, A., Rush, C.,
Eggleston, I.M., and van Aalten, D.M. (2011). Bisdionin C - a rationally de-Chemistry & Biology 18,signed, nanomolar inhibitor of family 18 chitinases. ACS Med. Chem. Lett.
published online March 23, 2011. 10.1021/ml200008b.
Schuttelkopf, A.W., and van Aalten, D.M. (2004). PRODRG: a tool for high-
throughput crystallography of protein-ligand complexes. Acta Crystallogr. D
Biol. Crystallogr. 60, 1355–1363.
Schuttelkopf, A.W., Andersen, O.A., Rao, F.V., Allwood, M., Lloyd, C.,
Eggleston, I.M., and van Aalten, D.M. (2006). Screening-based discovery
and structural dissection of a novel family 18 chitinase inhibitor. J. Biol.
Chem. 281, 27278–27285.
Sutherland, T.E., Maizels, R.M., and Allen, J.E. (2009). Chitinases and chiti-
nase-like proteins: potential therapeutic targets for the treatment of T-helper
type 2 allergies. Clin. Exp. Allergy 39, 943–955.
Terwisscha van Scheltinga, A.C., Armand, S., Kalk, K.H., Isogai, A., Henrissat,
B., and Dijkstra, B.W. (1995). Stereochemistry of chitin hydrolysis by a plant
chitinase/lysozyme and X-ray structure of a complex with allosamidin:
evidence for substrate assisted catalysis. Biochemistry 34, 15619–15623.
Vaaje-Kolstad, G., Houston, D.R., Rao, F.V., Peter, M.G., Synstad, B., van
Aalten, D.M., and Eijsink, V.G. (2004). Structure of the D142N mutant of the
family 18 chitinase ChiB from Serratia marcescens and its complex with allo-
samidin. Biochim. Biophys. Acta 1696, 103–111.
Vagin, A.A., and Teplyakov, A. (1997). MOLREP: an automated program for
molecular replacement. J. Appl. Cryst. 30, 1022–1025.
van Aalten, D.M., Komander, D., Synstad, B., Gaseidnes, S., Peter, M.G., and
Eijsink, V.G. (2001). Structural insights into the catalytic mechanism of a family
18 exo-chitinase. Proc. Natl. Acad. Sci. USA 98, 8979–8984.
Woodruff, P.G., Khashayar, R., Lazarus, S.C., Janson, S., Avila, P., Boushey,
H.A., Segal, M., and Fahy, J.V. (2001). Relationship between airway inflamma-
tion, hyperresponsiveness, andobstruction in asthma. J. AllergyClin. Immunol.
108, 753–758.
Yang, C.J., Liu, Y.K., Liu, C.L., Shen, C.N., Kuo, M.L., Su, C.C., Tseng, C.P.,
Yen, T.C., and Shen, C.R. (2009). Inhibition of Acidic Mammalian Chitinase
by RNA Interference Suppresses Ovalbumin-Sensitized Allergic Asthma.
Hum. Gene Ther. 20, 1597–1606.
Zaheer-ul-Haq, Dalal, P., Aronson, N.N., Jr., and Madura, J.D. (2007). Family
18 chitolectins: comparison of MGP40 and HUMGP39. Biochem. Biophys.
Res. Commun. 359, 221–226.
Zheng, T., Rabach, M., Chen, N.Y., Rabach, L., Hu, X., Elias, J.A., and Zhu, Z.
(2005). Molecular cloning and functional characterization of mouse chitotriosi-
dase. Gene 357, 37–46.
Zhu, Z., Zheng, T., Homer, R.J., Kim, Y.K., Chen, N.Y., Cohn, L., Hamid, Q.,
and Elias, J.A. (2004). Acidic mammalian chitinase in asthmatic Th2 inflamma-
tion and IL-13 pathway activation. Science 304, 1678–1682.569–579, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 579
